|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COMMD2 |
Gene summary for COMMD2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COMMD2 | Gene ID | 51122 |
| Gene name | COMM domain containing 2 | |
| Gene Alias | HSPC042 | |
| Cytomap | 3q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q86X83 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51122 | COMMD2 | P15T-E | Human | Esophagus | ESCC | 1.59e-61 | 1.21e+00 | 0.1149 |
| 51122 | COMMD2 | P16T-E | Human | Esophagus | ESCC | 1.11e-78 | 1.25e+00 | 0.1153 |
| 51122 | COMMD2 | P17T-E | Human | Esophagus | ESCC | 3.30e-11 | 7.21e-01 | 0.1278 |
| 51122 | COMMD2 | P19T-E | Human | Esophagus | ESCC | 3.93e-08 | 7.75e-01 | 0.1662 |
| 51122 | COMMD2 | P20T-E | Human | Esophagus | ESCC | 1.24e-42 | 9.64e-01 | 0.1124 |
| 51122 | COMMD2 | P21T-E | Human | Esophagus | ESCC | 3.52e-45 | 9.99e-01 | 0.1617 |
| 51122 | COMMD2 | P22T-E | Human | Esophagus | ESCC | 1.08e-49 | 8.96e-01 | 0.1236 |
| 51122 | COMMD2 | P23T-E | Human | Esophagus | ESCC | 6.91e-45 | 9.67e-01 | 0.108 |
| 51122 | COMMD2 | P24T-E | Human | Esophagus | ESCC | 3.49e-43 | 9.62e-01 | 0.1287 |
| 51122 | COMMD2 | P26T-E | Human | Esophagus | ESCC | 3.78e-59 | 1.10e+00 | 0.1276 |
| 51122 | COMMD2 | P27T-E | Human | Esophagus | ESCC | 4.03e-47 | 9.04e-01 | 0.1055 |
| 51122 | COMMD2 | P28T-E | Human | Esophagus | ESCC | 6.49e-54 | 1.09e+00 | 0.1149 |
| 51122 | COMMD2 | P30T-E | Human | Esophagus | ESCC | 1.28e-39 | 1.49e+00 | 0.137 |
| 51122 | COMMD2 | P31T-E | Human | Esophagus | ESCC | 7.28e-43 | 7.79e-01 | 0.1251 |
| 51122 | COMMD2 | P32T-E | Human | Esophagus | ESCC | 1.37e-71 | 1.49e+00 | 0.1666 |
| 51122 | COMMD2 | P36T-E | Human | Esophagus | ESCC | 1.34e-41 | 1.55e+00 | 0.1187 |
| 51122 | COMMD2 | P37T-E | Human | Esophagus | ESCC | 7.85e-50 | 9.52e-01 | 0.1371 |
| 51122 | COMMD2 | P38T-E | Human | Esophagus | ESCC | 1.81e-10 | 5.21e-01 | 0.127 |
| 51122 | COMMD2 | P39T-E | Human | Esophagus | ESCC | 4.36e-45 | 8.93e-01 | 0.0894 |
| 51122 | COMMD2 | P40T-E | Human | Esophagus | ESCC | 4.72e-25 | 6.96e-01 | 0.109 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COMMD2 | SNV | Missense_Mutation | novel | c.305N>C | p.Leu102Pro | p.L102P | Q86X83 | protein_coding | deleterious(0.01) | probably_damaging(0.915) | TCGA-EW-A6SB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | deletion | In_Frame_Del | c.100_102delNNN | p.Phe34del | p.F34del | Q86X83 | protein_coding | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| COMMD2 | SNV | Missense_Mutation | novel | c.478N>T | p.His160Tyr | p.H160Y | Q86X83 | protein_coding | tolerated(0.09) | benign(0.084) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | SNV | Missense_Mutation | c.517N>T | p.Leu173Phe | p.L173F | Q86X83 | protein_coding | tolerated(0.06) | possibly_damaging(0.626) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| COMMD2 | SNV | Missense_Mutation | c.387G>T | p.Trp129Cys | p.W129C | Q86X83 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| COMMD2 | SNV | Missense_Mutation | rs779093793 | c.586N>T | p.Arg196Cys | p.R196C | Q86X83 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| COMMD2 | SNV | Missense_Mutation | c.439G>A | p.Ala147Thr | p.A147T | Q86X83 | protein_coding | tolerated(0.44) | benign(0.003) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| COMMD2 | SNV | Missense_Mutation | novel | c.290A>G | p.Lys97Arg | p.K97R | Q86X83 | protein_coding | tolerated(0.25) | benign(0.018) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | SNV | Missense_Mutation | rs373377514 | c.49C>T | p.Pro17Ser | p.P17S | Q86X83 | protein_coding | tolerated(0.63) | benign(0.012) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COMMD2 | SNV | Missense_Mutation | novel | c.293N>C | p.Leu98Ser | p.L98S | Q86X83 | protein_coding | tolerated(0.4) | benign(0.081) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |